AFP and hepatocellular carcinoma: Although AFP combined with liver imaging remains a key biomarker for HCC diagnosis and monitoring, its specificity and sensitivity for the early-stage detection of HCC are considered suboptimal, with elevated levels detected in only 60–80% of HCC cases [15,28,29,30,31].